Press Releases

07.10.2017

Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress

06.30.2017

BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

06.29.2017

Alcyone Lifesciences Enters into a Feasibility Study Agreement with Pfizer to Evaluate Alcyone’s proprietary PulsarTM Advanced Intrathecal Precision Delivery Platform Technology for use in Gene Therapy Targeting Central Nervous System Disorders

06.27.2017

Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri

06.22.2017

Pfizer Declares 32-Cent Third-Quarter 2017 Dividend

06.19.2017

Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine

06.16.2017

Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

06.14.2017

Pfizer Receives Exclusive Commercialization Rights in Europe for CRESEMBA, a Novel Treatment for Potentially Life-Threatening Fungal Infections Among Immunocompromised Patients

06.13.2017

Nearly One in Four New and Expectant Parents Have Never Heard of Invasive Pneumococcal Disease According to a New Survey

06.13.2017

Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

06.10.2017

Merck and Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies

06.09.2017

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer